In 2017, the USPTF reversed the 2012 guidance advising against PSA-based screening in all men. The USPTF endorses individual decision-making for men aged 55-69 years only. Despite the guidance, the researchers found the mean rate of PSA testing increased by 12.5% (95% CI, 1.1%-24.4%). Notably, this included significant increases among men aged 40-54 years and those older than 70 years, for whom screening is not recommended.
Learn more about prostate cancer diagnosis.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Elwyn C. Cabebe. Rapid Review Quiz: Cancer Overdiagnosis - Medscape - Apr 08, 2022.
Comments